Avidity (RNA): Rega marang dodolan
The current P/S multiple reflects market expectations, where 585.30 represents the current metric value for Avidity Biosciences (RNA). This trend is driven by strong biotech patents that ensure high margins. Meanwhile, drug production is outsourced to third-party contractors, creating a dependency on their stability. In the future, successful clinical trials could grant the company monopoly pricing power over rare therapies.
Rincian analitis perusahaan Avidity (RNA)
- rega lan prakiraan konsensus rega:
- data kapitalisasi bursa:
- data nilai buku modal saham:
- indikator beban kredit lan likuiditas emiten:
Koefisien Total Utang marang Modal Avidity Biosciences|RNA - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal Avidity Corp|RNA - Utang perusahaan|Rasio utang marang nilai buku Avidity|RNA - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Avidity Biosciences|Likuiditas darurat aviditybiosciences.com
- data bathi resik lan rasio valuasi:
RNA - Bathi resik perusahaan|Prakiraan bathi perusahaan Avidity Biosciences|RNA - Rasio rega marang bathi|Pangali mangsa ngarep rega marang bathi Avidity Biosciences Inc|RNA - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan Avidity|RNA - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Avidity Biosciences|RNA - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan aviditybiosciences.com|RNA - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep Avidity Biosciences
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:aviditybiosciences.com (RNA)
For Avidity Biosciences (RNA), which operates in an undersaturated RNA therapeutics market, the P/S ratio reflects market expectations for future sales of innovative drugs. This metric is calculated as the ratio of market capitalization to annual revenue, measuring the value of each dollar of income in the eyes of investors. By analyzing the P/S chart, one can assess the extent to which the premium for breakthrough technologies is justified within the context of an expanding patient base.
Perusahaan pesaing
Koefisien rega marang pendapatan Tempus AI|Rasio rega marang pendapatan Qiagen QGEN|Ionis Pharmaceuticals, Inc. (IONS) - Rega marang dodolan|RGEN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan CRISPR CRSP|WGS: Multiplikator P/S|Kapitalisasi marang pendapatan ultragenyx.com|BEAM (Beam Therapeutics) - Multiplikator P/S|Sarepta Therapeutics (SRPT) - Koefisien rega marang pendapatan|Multiplikator P/S TWST|TXG - Rega marang dodolan|Rasio rega marang pendapatan Intellia Therapeutics NTLA|STOK: Rasio kapitalisasi marang pendapatan|BioLife Solutions - Multiplikator P/S|Wave Life Sciences Ltd (WVE) - Kapitalisasi marang pendapatan|MAZE: Multiplikator P/S|Rega marang dodolan Sionna Corp (SION)|Rasio rega marang pendapatan Prime Medicine, Inc.|tayshagtx.com (TSHA) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan uniQure (QURE)|MGTX (MeiraGTx Holdings) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Regenxbio RGNX|SLDB: Rasio kapitalisasi marang pendapatan|Ocugen, Inc. - Multiplikator P/S|PACB - Multiplikator P/S|BNTC: Multiplikator P/S|Rasio kapitalisasi marang pendapatan DSGN|Rasio rega marang pendapatan Rocket Pharmaceuticals Inc|Rasio kapitalisasi marang pendapatan FDMT (4D Molecular Corp)|Multiplikator P/S LXEO|Multiplikator P/S korrobio.com (KRRO)|Multiplikator P/S EDIT (Editas Medicine)|Multiplikator P/S Silence Therapeutics PLC SLN|PRQR: Kapitalisasi marang pendapatan|CDXS: Rasio rega marang pendapatan|SGMO: Multiplikator P/S|NAUT - Koefisien rega marang pendapatan|MGX (Metagenomi) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan DTIL (precisionbiosciences.com)|Multiplikator P/S GBIO|Koefisien rega marang pendapatan Boundless Bio Inc|Exicure - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan IMNN (Imunon Inc)|PHIO: Kapitalisasi marang pendapatan|Rega marang dodolan Mustang Bio, Inc.|RNAZ (transcodetherapeutics.com) - Kapitalisasi marang pendapatan|Bionano Genomics - Rasio kapitalisasi pasar marang pendapatan|APDN (Applied DNA Sciences) - Multiplikator P/S|Rasio rega marang pendapatan BLUE|Multiplikator P/S IPA|Koefisien rega marang pendapatan Omega Therapeutics Inc|Rasio rega marang pendapatan Singular Genomics Systems Inc OMIC|Regulus (RGLS) - Rega marang dodolan|SYRS - Rasio rega marang pendapatan|Koefisien rega marang pendapatan telesisbio.com TBIO|TCON: Multiplikator P/S|Kapitalisasi marang pendapatan Unity Biotechnology Inc.
